Visionary Surgical Advancement [Tuesday, February 17, 2009]
by Sandra J. Freer

Attention News Editors: Acri.LISA(R) Lens - a Visionary Surgical Advancement from Carl Zeiss - Revolutionizes existing technology

Multifocal intraocular lenses (IOLs) are the most exciting advance in cataract and presbyopia corrective surgery in 25 years; meeting the expectations of a growing population striving for an active life with minimal or no support from eye glasses.

TORONTO , Feb. 17 /CNW/ - The mission over the years has been to provide a surgical application for multifocal vision correction. Patients wanted to improve their quality of life and surgeons wanted a product with a predictability of vision results and high patient satisfaction.

Dr. Christoph Kranemann, a leader in ophthalmology, laser eye surgery and complex cataract and glaucoma surgery, was the first surgeon in Canada to provide a new remarkable surgical solution. "I chose the Acri.LISA(R) lens because by design it is least likely to give patients any undesirable side effects. Comparatively it has been a challenge to give people a quick and good intermediate vision by using the same lens in both eyes."

Dr. Kranemann's first patient was Hannelore, a 63 year old woman. She had worn glasses since adolescence, but since her early 50's was having a rapid decline in her vision. Hannelore explained, "I was constantly needing new eye glasses because my eyesight was changing every few months, and to make matters worse, each eye needed a different correction. It was not unusual for me to carry several pairs of glasses for different tasks such as reading - which was often fuzzy, walking, using the computer and driving. Night-time driving was not possible and I was restricted in my normal activities, always trying to maintain my ability to see."

Hannelore's condition is not that uncommon and the Acri.LISA(R) lens was designed to allow patients to see close-up, distant and in-between without relying on a collection of eye glasses. Hannelore recalled, "I had my first eye operated on Oct.2nd, 2008. I was very anxious, yet very hopeful. To my amazement I could see more clearly immediately, right after the surgery and by the following day I could see things I never could before."

Dr. Kranemann, pleased with the results, observed that there were "No negative symptoms post-op". He performed the second surgery the same month on Oct. 30th 2008. He detailed, "There are limitations with other technologies, including halos and glares - particularly in the first six months, compounding a challenge for a mix and match system lens to address near, distance and intermediate vision."

Hannelore was thrilled. "It was a miracle and even though both of my eyes had different vision issues, now I don't need to wear any glasses at all. I can even see to pluck my eyebrows. My life has totally changed. I feel independent. I can even drive at night."

Dr. Kranemann stated, "the most significant difference post-op was true ecstatic patient responses and they have reported absolutely no negative symptoms whatsoever. I look forward to using this product more frequently and I feel that the Acri.LISA(R) lens is certainly very promising."

Dr. Kranemann will continue to obtain long-term data to collaborate his initial results and plans to present his findings on the Acri.LISA(R) lens to his peers at various upcoming meetings of the Ophthalmology Societies.

Acri.LISA(R) - Improving the Quality of Life

Brief profile: Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions which enable doctors to improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat ophthalmic diseases. In the field of Neuro/ENT surgery the Company provides innovative visualization solutions. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiotherapy.

The Company's around 2,100 employees generated revenue of about EUR 600 million in fiscal year 2007/08 (ended Sept. 30). The headquarters of Carl Zeiss Meditec are located in Jena , Germany . In addition to other subsidiaries in Germany , the Company is represented by over 50 percent of its employees at sites in the USA , Japan , Spain and France . Thirty-five percent of Carl Zeiss Meditec's shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world's leading groups engaged in the optical and opto-electronics industry. The five independently run business segments of Carl Zeiss AG operate in the future-oriented markets "Medical and Research Solutions", "Industrial Solutions" and "Lifestyle Products". Carl Zeiss AG is headquartered in Oberkochen , Germany . During fiscal year 2007/08 (ended Sept. 30) the company generated revenues of about EUR 2.7 billion. Carl Zeiss has around 13,000 employees in more than 30 countries, including more than 8,000 in Germany . -30- For further information please visit our website at: www.meditec.zeiss.com For further information: MEDIA CONTACT: For more information or to arrange an interview with Dr. Kranemann please contact: Sandra Freer, SDA Communications at (416) 239-0781, info@sdapublishing.com ; Acri.LISA(R) Lens - Carl Zeiss Canada Ltd., Toronto , Ontario , amaraldo@zeiss.com , www.zeiss.ca